UCLA Prostate Cancer Index
The UCLA Prostate Cancer Index (UCLA PCI) is a 20-item, prostate-cancer-specific quality-of-life instrument focused on functional outcomes (urinary, sexual, bowel) rather than general cancer QoL. Developed by Litwin et al. in 1998, it has become the standard functional assessment tool in prostate cancer outcomes research, particularly for treatment comparison studies evaluating surgical vs. radiation outcomes.
Rekod sumber
Petikan disalin secara verbatim daripada rekod sumber kaedah. Tiada pengesahan peringkat tuntutan disimpulkan daripadanya.
- Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., & Brook, R. H. (1998). The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care, 36(7), 1002–1012. · DOI 10.1097/00005650-199807000-00007
- Litwin, M. S., & Tan, H. J. (2017). The diagnosis and treatment of prostate cancer: a review. JAMA, 317(24), 2532–2542. · DOI 10.1001/jama.2017.7248
Tuntutan yang dikurasi
Tuntutan disimpan dalam lejar bukti, setiap satu dengan penilaiannya sendiri.
Pandangan ini tidak mencipta penilaian tuntutan apabila lejar tiada.
Kaedah berkaitan
Dijana daripada graf kaedah dan ditunjukkan sebagai perhubungan yang dicadangkan mesin — tiada tuntutan bukti disimpulkan.